Loredana Puca

5.8k total citations · 1 hit paper
22 papers, 1.6k citations indexed

About

Loredana Puca is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Loredana Puca has authored 22 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Loredana Puca's work include Prostate Cancer Treatment and Research (14 papers), Lung Cancer Research Studies (8 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). Loredana Puca is often cited by papers focused on Prostate Cancer Treatment and Research (14 papers), Lung Cancer Research Studies (8 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). Loredana Puca collaborates with scholars based in United States, Italy and Israel. Loredana Puca's co-authors include Himisha Beltran, Panagiotis J. Vlachostergios, Andrea Sboner, Olivier Elemento, Juan Miguel Mosquera, David M. Nanus, Scott T. Tagawa, Mark A. Rubin, Joanna Cyrta and Matteo Benelli and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Nature Communications.

In The Last Decade

Loredana Puca

22 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

2016 1.1k citations Himisha Beltran, Davide Prandi et al. Nature Medicine profile →

Peers

Countries citing papers authored by Loredana Puca

Since Specialization

Citations

This map shows the geographic impact of Loredana Puca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Loredana Puca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Loredana Puca more than expected).

Fields of papers citing papers by Loredana Puca

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Loredana Puca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Loredana Puca. The network helps show where Loredana Puca may publish in the future.

Co-authorship network of co-authors of Loredana Puca

This figure shows the co-authorship network connecting the top 25 collaborators of Loredana Puca. A scholar is included among the top collaborators of Loredana Puca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Loredana Puca. Loredana Puca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Notch signaling suppresses neuroendocrine differentiation and alters the immune microenvironment in advanced prostate cancer 2024 ·Journal of Clinical Investigation ·Sheng‐Yu Ku, (unknown), (unknown), Yasutaka Yamada, Kei Mizuno, Mark D. Long, Spencer R. Rosario, Meenalakshmi Chinnam, (unknown), Loredana Puca, Min Jin Kim, Martin Bakht, Varadha Balaji Venkadakrishnan, Brian D. Robinson, Andrés Acosta, Kristine M. Wadosky, Juan Miguel Mosquera, David W. Goodrich, Himisha Beltran	16
2	Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes 2024 ·Nature Communications ·Varadha Balaji Venkadakrishnan, (unknown), Richa Singh, Matthew A. Booker, Nicole A. Traphagen, (unknown), (unknown), Navin R. Mahadevan, Kei Mizuno, Loredana Puca, (unknown), Sheng‐Yu Ku, Martin Bakht, Ashir A. Borah, Zachary T. Herbert, Michael Tolstorukov, David A. Barbie, David S. Rickman, Myles Brown, Himisha Beltran	20
3	SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy 2020 ·Molecular Cancer Therapeutics ·Vincenza Conteduca, Sheng‐Yu Ku, Loredana Puca, (unknown), (unknown), Judy Hess, Rohan Bareja, Panagiotis J. Vlachostergios, Michael Sigouros, Juan Miguel Mosquera, Andrea Sboner, David M. Nanus, Olivier Elemento, Ryan Dittamore, Scott T. Tagawa, Himisha Beltran	46
4	N-Myc–mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer 2019 ·Journal of Clinical Investigation ·Adeline Berger, Nicholas J. Brady, Rohan Bareja, Brian Robinson, Vincenza Conteduca, Michael A. Augello, Loredana Puca, Adnan Ahmed, Étienne Dardenne, Xiaodong Lü, Inah Hwang, (unknown), Andrea Sboner, Olivier Elemento, Jihye Paik, Jindan Yu, Christopher E. Barbieri, Noah Dephoure, Himisha Beltran, David S. Rickman	116
5	First-in-field small molecule inhibitors targeting BRN2 as a therapeutic strategy for small cell prostate cancer. 2019 ·Journal of Clinical Oncology ·Daksh Thaper, (unknown), (unknown), Sahil Kumar, Soojin Kim, Sepideh Vahid, Olena Sivak, A.H. Aguda, Loredana Puca, Himisha Beltran, Amina Zoubeidi	3
6	Abstract 1295: First-in-field small molecule inhibitors targeting BRN2 as a therapeutic strategy for small cell prostate cancer 2019 ·Daksh Thaper, (unknown), (unknown), Sahil Kumar, Soojin Kim, Olena Sivak, A.H. Aguda, Dwaipayan Ganguli, Sepideh Vahid, Loredana Puca, Himisha Beltran, Amina Zoubeidi	1
7	SLFN11 expression (exp) in castration-resistant prostate cancer (CRPC) patients (pts) to predict response to platinum-based chemotherapy (PLT). 2019 ·Journal of Clinical Oncology ·Vincenza Conteduca, Loredana Puca, Sheng‐Yu Ku, Judy Hess, (unknown), (unknown), Rohan Bareja, Panagiotis J. Vlachostergios, Michael Sigouros, Juan Miguel Mosquera, Andrea Sboner, David M. Nanus, Olivier Elemento, Ryan Dittamore, Scott T. Tagawa, Himisha Beltran	1
8	Abstract 2099: N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer 2019 ·Cancer Research ·Adeline Berger, Nicholas J. Brady, Rohan Bareja, Brian Robinson, Vincenza Conteduca, Michael A. Augello, Loredana Puca, Adnan Ahmed, Xiaodong Lu, Inah Hwang, (unknown), Andrea Sboner, Olivier Elemento, Jihye Paik, (unknown), Christopher E. Barbieri, Noah Dephoure, Himisha Beltran, David S. Rickman	1
9	Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies 2018 ·Cold Spring Harbor Perspectives in Medicine ·Loredana Puca, Panagiotis J. Vlachostergios, Himisha Beltran	82
10	Abstract 1947: Rovalpituzumab tesirine as a therapeutic agent for neuroendocrine prostate cancer 2018 ·Cancer Research ·Loredana Puca, (unknown), (unknown), Étienne Dardenne, Kumiko Isse, Michael Sigouros, David M. Nanus, Scott T. Tagawa, Juan Miguel Mosquera, Laura R. Saunders, Himisha Beltran	2
11	Emerging Variants of Castration-Resistant Prostate Cancer 2017 ·Current Oncology Reports ·Panagiotis J. Vlachostergios, Loredana Puca, Himisha Beltran	142
12	199 Impairment of notch 1 signaling is a common defect in lesions from patients with hidradenitis suppurativa 2017 ·Journal of Investigative Dermatology ·C. Gall, Loredana Puca, Marine Madrange, (unknown), (unknown), Yamina Hamel, (unknown), Christel Brou, H. Bachelez, Asma Smahi	2
13	Abstract 992: Patient-derived tumor organoids of neuroendocrine prostate cancer 2017 ·Cancer Research ·Loredana Puca, Rohan Bareja, Reid Shaw, Wouter R. Karthaus, Dong Gao, Chantal Pauli, Juan Miguel Mosquera, Joanna Cyrta, Rachele Rosati, Rema Rao, Andrea Sboner, Carla Grandori, Giorgio Inghirami, Yu Chen, Mark A. Rubin, Himisha Beltran	1
14	Rovalpituzumab tesirine (Rova-T) as a therapeutic agent for Neuroendocrine Prostate Cancer (NEPC). 2017 ·Journal of Clinical Oncology ·Loredana Puca, Verena Sailer, Kaitlyn Gayvert, Kumiko Isse, Michael Sigouros, David M. Nanus, Scott T. Tagawa, Juan Miguel Mosquera, Laura R. Saunders, Himisha Beltran	5
15	A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC) 2016 ·Annals of Oncology ·(unknown), Daniel C. Danila, Bruce Montgomery, Russell Z. Szmulewitz, Ulka N. Vaishampayan, Andrew J. Armstrong, Mark N. Stein, Christopher Hoimes, J. Pinski, Howard I. Scher, Loredana Puca, Rohan Bareja, Wai Wong, Mark A. Rubin, Juan Miguel Mosquera, Andrea Sboner, Clara Oromendia, David M. Nanus, Karla V. Ballman, (unknown)	11
16	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer breakdown → 2016 ·Nature Medicine ·Himisha Beltran, Davide Prandi, Juan Miguel Mosquera, Matteo Benelli, Loredana Puca, Joanna Cyrta, Clarisse Marotz, Ευγενία Γιαννοπούλου, Balabhadrapatruni V. S. K. Chakravarthi, Sooryanarayana Varambally, Scott A. Tomlins, David M. Nanus, Scott T. Tagawa, Eliezer M. Van Allen, Olivier Elemento, Andrea Sboner, Levi A. Garraway, Mark A. Rubin, Francesca Demichelis	1062
17	Abstract 619: Personalized models to guide precision medicine 2016 ·Cancer Research ·Chantal Pauli, Loredana Puca, Brooke M. Emerling, (unknown), Andrea Sboner, Olivier Elemento, Juan Miguel Mosquera, Himisha Beltran, Mark A. Rubin	1
18	An emerging role for cytopathology in precision oncology 2015 ·Cancer Cytopathology ·Chantal Pauli, Loredana Puca, Juan Miguel Mosquera, Brian D. Robinson, Himisha Beltran, Mark A. Rubin, Rema Rao	14
19	α-Arrestins – new players in Notch and GPCR signaling pathways in mammals 2014 ·Journal of Cell Science ·Loredana Puca, Christel Brou	44
20	α-arrestin 1 (ARRDC1) and β-arrestins cooperate to mediate Notch degradation in mammals 2013 ·Journal of Cell Science ·Loredana Puca, Patricia Chastagner, Vannary Meas‐Yedid, Alain Israël, Christel Brou	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact